- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Interventions
- Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,031 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 27
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 25
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Panitumumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Capecitabine, Quality-of-Life Assessment, Laboratory Biomarker Analysis
- Biological · Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Gastrointestinal Cancer
- Interventions
- Oxaliplatin, Capecitabine, Leucovorin, 5-fluorouracil, radiation
- Drug · Radiation
- Lead sponsor
- Tannaz Armaghany
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Houston, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Olaparib, 5-FU, Bevacizumab, Capecitabine, Leucovorin/ levoleucovorin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Burbank, California • Fullerton, California • Colorado Springs, Colorado + 19 more
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
- Interventions
- DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 twice daily (BID), Leucovorin Calcium, Fluorouracil
- Drug
- Lead sponsor
- Leap Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, capecitabine, fluorouracil, leucovorin calcium, oxaliplatin
- Biological · Drug
- Lead sponsor
- Prologue Research International
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Greenbrae, California + 47 more
- Conditions
- Colorectal Neoplasms
- Interventions
- GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab
- Drug
- Lead sponsor
- Seattle Project Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 43
- States / cities
- Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more
- Conditions
- Cancer
- Interventions
- Leucovorin, Fluorouracil - bolus, Bevacizumab, Fluorouracil - infusion, ABT-165, Irinotecan
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 46
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 39 more
- Conditions
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Esophagogastroduodenoscopy, Fluorouracil, Hypofractionated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Positron Emission Tomography, Survey Administration, Docetaxel, Durvalumab
- Procedure · Drug · Radiation + 2 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Neoplasms
- Interventions
- 5-FU, Docetaxel, Enzalutamide, Ipatasertib, Leucovorin, Oxaliplatin, Paclitaxel
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 7
- States / cities
- San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 4 more
- Conditions
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- Interventions
- Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP)
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 30
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
- Interventions
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
- Drug
- Lead sponsor
- Neonc Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Modified Bolus 5-FU/LV with Irinotecan, FOLFIRI + bevacizumab, miFL + bevacizumab, Infusional 5-FU/LV with Irinotecan, Oral Capecitabine with Irinotecan
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 547 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 141
- States / cities
- Birmgingham, Alabama • Birmingham, Alabama • Birmngham, Alabama + 123 more
- Conditions
- Colorectal Cancer
- Interventions
- Simtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil
- Biological · Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 56
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more
- Conditions
- Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
- Interventions
- Avelumab, Oxaliplatin, 5-Fluorouracil, Leucovorin, Capecitabine, Best supportive care
- Drug · Other
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 35
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma
- Interventions
- Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Ascorbic Acid
- Drug · Dietary Supplement
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gastroesophageal Adenocarcinoma
- Interventions
- Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU), FLOT Chemotherapy, Calcium folinate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- Newark, Delaware • Washington D.C., District of Columbia • Fairway, Kansas + 3 more
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
- Interventions
- intensity-modulated radiation therapy, fluorouracil, oxaliplatin, leucovorin calcium, therapeutic conventional surgery
- Radiation · Drug · Procedure
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 12
- States / cities
- Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan, Nivolumab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 786
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 504 more
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Utidelone Capsule, Fluoropyrimidine- and Platinum-containing Therapy, Oxaliplatin, PD-1 inhibitor, Capecitabine
- Drug
- Lead sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Gastric Cancer
- Interventions
- 5-Fluorouracil, Ipatasertib, Leucovorin, Oxaliplatin, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Colorectal Neoplasms
- Interventions
- 5-fluorouracil, bevacizumab, capecitabine, irinotecan, folinic acid, oxaliplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 45
- States / cities
- Mobile, Alabama • Long Beach, California • Los Angeles, California + 41 more
- Conditions
- Colorectal Cancer
- Interventions
- Ramucirumab, Placebo, Irinotecan, Folinic Acid, 5-Fluorouracil
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,072 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 92
- States / cities
- Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more